Process for preparing soft, elastic polyurethane
    1.
    发明授权
    Process for preparing soft, elastic polyurethane 有权
    制备柔软,弹性聚氨酯的方法

    公开(公告)号:US06527995B1

    公开(公告)日:2003-03-04

    申请号:US09610832

    申请日:2000-07-06

    IPC分类号: D04H154

    摘要: A process for producing a thermoplastic polyurethane film by means of sintering a particulate thermoplastic polyurethane in a heated mold, is described. The thermoplastic polyurethane has: (i) a melt index of 20 to 100, measured at 190° C. and under an applied force of 21.2 N; (ii) a relative solution viscosity of 1.15 to 1.45, the relative solution viscosity being determined by, measuring the viscosity (a) of a solution of 0.4 grams of the thermoplastic polyurethane in 99.7 grams N-methyl-2-pyrrolidone containing 0.1% dibutylamine at 25° C., measuring the viscosity (b) of N-methyl-2-pyrrolidone containing 0.1% dibutylamine at 25° C., and dividing viscosity (a) by viscosity (b); and (iii) a Shore hardness of 80 to 98.

    摘要翻译: 描述了通过在加热的模具中烧结颗粒状热塑性聚氨酯来制造热塑性聚氨酯膜的方法。 热塑性聚氨酯具有:(i)在190℃和21.2N的施加力下测量的20至100的熔体指数; (ii)相对溶液粘度为1.15至1.45,相对溶液粘度通过测量在含有0.1%二丁胺的99.7克N-甲基-2-吡咯烷酮中的0.4克热塑性聚氨酯溶液的粘度(a) 在25℃下测量在25℃下含有0.1%二丁胺的N-甲基-2-吡咯烷酮的粘度(b),并将粘度(a)除以粘度(b)。 和(iii)肖氏硬度为80-98。

    INHIBITORS OF TGF-R SIGNALING FOR TREATMENT OF CNS DISORDERS
    6.
    发明申请
    INHIBITORS OF TGF-R SIGNALING FOR TREATMENT OF CNS DISORDERS 有权
    TGF-R信号传导治疗CNS疾病的抑制剂

    公开(公告)号:US20110263678A1

    公开(公告)日:2011-10-27

    申请号:US13028035

    申请日:2011-02-15

    摘要: The present invention relates to the use of oligonucleotides for the preparation of a pharmaceutical composition for the prevention or treatment of a disease, wherein neurogenesis and/or neuroregeneration has a beneficial effect, in particular a disease like Morbus Alzheimer, Morbus Parkinson, Lewy Body Dementia,—Amyotrophic Lateral Sclerosis, Spinocerebellar Atrophies, Creutzfeldt Jakob Disease, Frontemporal Dementia, Morbus Pick, AIDS Dementia Complex, Vascular Dementia, Progressive Supranuclear Palsy, Corticobasal Degeneration, Multisystem-Atrophy, Hallervorden Spatz Disease, Huntington's disease, Stroke, Traumatic Brain and spinal cord Injury, Retinitis Pigmentosa, Macular Degeneration, Glaucoma, Cochlea Degeneration, Depression, Schizophrenia, Multiple Sclerosis, and developmental neurodegeneration.

    摘要翻译: 本发明涉及寡核苷酸用于制备用于预防或治疗疾病的药物组合物的用途,其中神经发生和/或神经再生具有有益效果,特别是诸如Morbus阿尔茨海默氏症,Morbus帕金森氏病,路易体痴呆症 ,肌营养不良性侧索硬化症,脊髓小脑萎缩症,Creutzfeldt雅各布病,前痴呆症,Morbus Pick,艾滋病痴呆综合征,血管性痴呆,进行性核核性麻痹,皮质基底退化,多系统萎缩,Hallervorden Spatz病,亨廷顿氏病,中风,创伤性脑和脊髓 脐带损伤,视网膜色素变性,黄斑变性,青光眼,耳蜗变性,抑郁,精神分裂症,多发性硬化和发育性神经变性。

    Preparation of polyetherols
    9.
    发明授权
    Preparation of polyetherols 失效
    聚醚类的制备

    公开(公告)号:US06563007B2

    公开(公告)日:2003-05-13

    申请号:US09915601

    申请日:2001-07-26

    IPC分类号: C07C2700

    摘要: Polyetherols based on solid initiator substances and liquid, hydroxyl-containing coinitiators are prepared by a catalyzed addition reaction of alkylene oxides by a process in which the initiator combination contains diols carrying ethoxy structures, the ratio of the average number of hydroxyl groups per mole of initiator combination to the number of ethoxy structures in the polyetherol being from 1:0.2 to 1:1.8 and the ratio of the amounts by weight of the diols carrying ethoxy structures to the average molecular weight of the polyetherol being from 1:2 to 1:15. The polyetherols prepared by this process are used for the preparation of PUR, in particular, rigid PUR foams.

    摘要翻译: 基于固体引发剂物质和液体的含羟基的共聚引发剂的聚醚系通过环氧烷的催化加成反应制备,其中引发剂组合含有载有乙氧基结构的二醇,每摩尔引发剂的平均羟基比例 与聚乙烯醇中的乙氧基结构的数量的组合为1:0.2至1:1.8,并且负载乙氧基结构的二醇的重量比与聚己二酸酯的平均分子量的比例为1:2至1:15 。 通过该方法制备的聚醚酯用于制备PUR,特别是刚性PUR泡沫。

    Inhibitors of TGF-R-signaling for treatment of CNS disorders
    10.
    发明授权
    Inhibitors of TGF-R-signaling for treatment of CNS disorders 有权
    抑制TGF-R信号传导治疗CNS疾病

    公开(公告)号:US08022045B1

    公开(公告)日:2011-09-20

    申请号:US10597813

    申请日:2005-02-09

    IPC分类号: C12N15/11 C07H21/02 C07H21/04

    摘要: The present invention relates to the use of oligonucleotides for the preparation of a pharmaceutical composition for the prevention or treatment of a disease, wherein neurogenesis and/or neuroregeneration has a beneficial effect, in particular a disease like Morbus Alzheimer, Morbus Parkinson, Lewy Body Dementia, Amyotrophic Lateral Sclerosis, Spinocerebellar Atrophies, Creutzfeldt Jakob Disease, Frontemporal Dementia, Morbus Pick, AIDS Dementia Complex, Vascular Dementia, Progressive Supranuclear Palsy, Corticobasal Degeneration, Multisystem-Atrophy, Hallervorden Spatz Disease, Huntington's disease, Stroke, Traumatic Brain and spinal cord Injury, Retinitis Pigmentosa, Macular Degeneration, Glaucoma, Cochlea Degeneration, Depression, Schizophrenia, Multiple Sclerosis, and developmental neurodegeneration.

    摘要翻译: 本发明涉及寡核苷酸用于制备用于预防或治疗疾病的药物组合物的用途,其中神经发生和/或神经再生具有有益效果,特别是诸如Morbus阿尔茨海默氏症,Morbus帕金森氏病,路易体痴呆症 ,肌萎缩性侧索硬化症,脊髓小脑萎缩症,Creutzfeldt雅各布病,前痴呆症,Morbus拣选,艾滋病痴呆复合物,血管性痴呆,进行性核核麻痹,皮质基底变性,多系统萎缩,霍氏阴道病,亨廷顿病,中风,创伤性脑和脊髓 损伤,色素性视网膜炎,黄斑变性,青光眼,耳蜗变性,抑郁,精神分裂症,多发性硬化和发育性神经变性。